Compare AbbVie Inc (ABBV) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

PALL trades at $23.15, up 1.05% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. A 1-for-5 stock split is scheduled for May 18, 2026. Recent news highlights palladium's price weakness as a potential buying opportunity, citing supply risks and industrial demand. The stock faces headwinds from Federal Reserve rate hike expectations and weaker investment demand.

The outlook remains cautious due to bearish technicals and macroeconomic pressures, though some analysts see value at current levels. Key risks include commodity price volatility and interest rate sensitivity. Investors should weigh the ETF's exposure to palladium's supply-demand dynamics against broader market sentiment.